Company: EDSA
Filing Date: 2025-09-09
Form Type: 424B5
Source: 0001171843-25-005799
Chunk: 10

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 424B5
Chunk 10
---
 at this location is (289) 800-9600. Our website
address is www.edesabiotech.com. The information contained on, or that can be accessed through, our website is not a part of this prospectus.
Our trademarks and trade names include, but may not be limited to, “Edesa Biotech,” and the Edesa logo.

#### Smaller Reporting Company – Scaled Disclosure
Pursuant to Item 10(f) of Regulation
S-K promulgated under the Securities Act, we have elected to comply with the scaled disclosure requirements applicable to “smaller
reporting companies,” including providing two years of audited financial statements.

| S-5 |

### THE OFFERING
| Common Shares Offered by Us                      |     | Common shares having an aggregate offering price of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
 up to $4,006,544.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Common Shares Outstanding Prior to This Offering |     | 7,037,648 common shares.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Common Shares Outstanding After This Offering    |     | Up to 8,621,262 shares, assuming the sale of up to 1,583,614 common shares at a price of $2.53 per share, which was the closing price of our common shares on Nasdaq on September 5, 2025. The actual number of shares issued will vary depending on the sales price under this offering.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Plan of Distribution                             |     | Sales of our common shares, if any, under this prospectus supplement and the accompanying prospectus may be made by any method permitted by law deemed to be an “at-the-market” offering as defined in Rule 415(a)(4) of the Securities Act, including without limitation sales made directly on Nasdaq, on any other existing trading market for the common shares in the United States, and directly to Wainwright as principal. The Sales Agent is not required to sell any certain number of shares or dollar amount of our common shares, but will act as a Sales Agent and use commercially reasonable efforts to sell on our behalf all of the common shares requested to be sold by us, consistent with its normal trading and sales practices, subject to the terms of the Sales Agreement. See “Plan of Distribution” on page S-21. |
| Use of Proceeds                                  |     | We intend to use the net proceeds from this offering for general corporate purposes, which may include working